Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...
ROCK ISLAND ARSENAL, Illinois (Sept. 9, 2025) – Army Contracting Command-Rock Island’s Source Selection Support Center of Excellence (S3COE) team, which consists of Jacob Harrison, lead procurement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results